| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24051 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2008-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c802554fabb02e290809713c8272251
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeb31c996bd46a0d42ee46315505e5b5 |
| publicationDate |
2021-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2840725-T3 |
| titleOfInvention |
Production procedure |
| abstract |
A method of producing a mammalian cell line that produces at least one antibody, a derivative thereof, or an antigen-binding fragment thereof comprising the steps of: (a) transforming a mammalian cell with a polynucleotide sequence comprising (i) a sequence encoding the antibody, a derivative thereof, or the antigen-binding fragment having a codon adaptation index that is equal to or greater than 0.9; and (ii) a sequence encoding a selection marker that is capable of providing amplification of the polynucleotide sequence; (b) providing at least one round of amplification in the presence of a selection and amplification agent; and (c) selecting the mammalian cell line once a cell production yield of 0.3-1.5 g / L has been achieved in prolonged non-fed batch cultures and / or a cell productivity of 10-100 pg. / cell / day in non-fed batch cultures of the antibody, a derivative thereof, or the antigen-binding agent; wherein the concentration of the selection and amplification agent is 50% or less than the concentration used to achieve an equivalent production yield, compared to a mammalian cell of (a) transformed with said polynucleotide sequence encoding the antibody , a derivative thereof or the antigen-binding fragment and has a codon adaptation index that is less than 0.9. |
| priorityDate |
2007-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |